China's First Biotech M&A Deal In 2022 Signals Busy Season Ahead?

 
• By Dexter Jie Yan

CSPC acquires a little-known Guangzhou biotech to kick-start China's pharma sector consolidation in 2022, a key goal outlined in the country's recent 14th Five-Year Plan.

More and more Chinese Biotechs are teaming up with larger-scale domestic pharma companies for wider market access.
2022's first bolt-on acquisition in China signals a trend worth watching • Source: Alamy

More from China

More from Focus On Asia